COMPANY

Repligen

HQ: Waltham, MA source · repligen.com ↗ · New England

73 open jobs · last seen Oct 23, 2026 · 28 sources

Location: Waltham, MA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Autism Bipolar I Depression Pancreatitis Bipolar Depression Mitochondrial Diseases RG1068 (synthetic human secretin) RG2417 Uridine RG2133 (2',3',5'-tri-O-acetyluridine)

73Open jobs 6Trials (company is sponsor)22NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Field Service Engineer II	2 locations, including South Korea, Remote	Oct 23, 2026	Oct 9, 2026
Senior Maintenance Technician	Rancho Dominguez, CA	Oct 21, 2026	Oct 9, 2026
Sr. Field Service Analytics Manager	52 locations (listed on the posting)	Oct 20, 2026	Oct 9, 2026
Development Engineer II	Molndal, Sweden	Oct 20, 2026	Oct 9, 2026
Bioprocessing Account Manager	Remote - Massachusetts	Oct 20, 2026	Oct 21, 2026

See all 73 jobs

Timeline

Oct 9, 2026 Board tracked Radar started tracking this company’s job board (73 open jobs at last check). source ↗
2008-11 Trial start Phase 2: A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression source ↗
2008-03 Trial start Phase 3: Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas source ↗
2006-03 Trial start II: Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression source ↗
2002-04 Trial start Phase 3: Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction source ↗
2002-04 Trial start Phase 3: Synthetic Human Secretin in Children With Autism source ↗

Open jobs 73

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Field Service Engineer II	2 locations, including South Korea, Remote	Oct 23, 2026	Oct 9, 2026	Mid
Senior Maintenance Technician	Rancho Dominguez, CA	Oct 21, 2026	Oct 9, 2026	Senior
Sr. Field Service Analytics Manager	52 locations (listed on the posting)	Oct 20, 2026	Oct 9, 2026	Senior
Development Engineer II	Molndal, Sweden	Oct 20, 2026	Oct 9, 2026	Mid
Bioprocessing Account Manager	Remote - Massachusetts	Oct 20, 2026	Oct 21, 2026	Not stated
Field Applications Scientist	4 locations, including Massachusetts, Remote	Oct 19, 2026	Oct 20, 2026	Not stated
Quality Control Analyst II	Marlborough, MA	Oct 18, 2026	Oct 19, 2026	Not stated
Pricing Manager	55 locations (listed on the posting)	Oct 16, 2026	Oct 17, 2026	Not stated
Technical Support Engineer II	4 locations (listed on the posting)	Oct 16, 2026	Oct 17, 2026	Not stated
Manager, Field Service	6 locations, including Pennsylvania, Remote	Oct 16, 2026	Oct 17, 2026	Not stated
Manager, Field Service	Remote - California	Oct 16, 2026	Oct 17, 2026	Not stated
Field Service Engineer II	Remote - New York	Oct 16, 2026	Oct 17, 2026	Not stated
Senior Manager, Engineering	Remote - Washington	Oct 15, 2026	Oct 16, 2026	Not stated
Technical Support Engineer I	4 locations, including Germany, Remote	Oct 15, 2026	Oct 16, 2026	Not stated
Bioprocessing Sales Specialist	Remote - Germany	Oct 15, 2026	Oct 16, 2026	Not stated
Warehouse Associate II	Waltham, MA	Oct 15, 2026	Oct 16, 2026	Not stated
Senior Quality Engineer	Rancho Dominguez, CA	Oct 13, 2026	Oct 9, 2026	Senior
Bioprocessing Sales Specialist	5 locations, including New Jersey, Remote	Oct 13, 2026	Oct 14, 2026	Senior
Logistics & Shipping Specialist	Ravensburg, Germany	Oct 13, 2026	Oct 14, 2026	Mid
Systems Engineer II	Tallinn, Estonia	Oct 12, 2026	Oct 9, 2026	Mid
Bioprocessing Account Manager	Remote - Massachusetts	Oct 12, 2026	Oct 9, 2026	Mid
Technical Support Engineer I	Tallinn, Estonia	Oct 9, 2026	Oct 9, 2026	Entry
Manufacturing Associate I	Hopkinton, MA	Oct 8, 2026	Oct 9, 2026	Entry
Director, Product Management	Waltham, MA	Oct 8, 2026	Oct 9, 2026	Senior
Technical Support Engineer II	5 locations, including India, Remote	Oct 8, 2026	Oct 9, 2026	Mid
Director, Business Unit Finance	Remote - Washington	Oct 6, 2026	Oct 9, 2026	Senior
Executive Assistant	Waltham, MA	Oct 6, 2026	Oct 9, 2026	Mid
Executive Assistant	Waltham, MA	Oct 6, 2026	Oct 9, 2026	Mid
Global Strategic Accounts Director	Remote - Netherlands	Oct 6, 2026	Oct 9, 2026	Senior
Services Sales & Contracts Specialist I	Remote - Germany	Oct 5, 2026	Oct 9, 2026	Entry
Business Development Director, Integrated Solutions	13 locations (listed on the posting)	Oct 2, 2026	Oct 9, 2026	Senior
Senior Process Technician	Waterford, Ireland	Oct 2, 2026	Oct 9, 2026	Senior
Manufacturing Associate	Waterford, Ireland	Oct 2, 2026	Oct 9, 2026	Entry
Accountant	Breda, Netherlands	Oct 2, 2026	Oct 9, 2026	Mid
Business Development Director, Integrated Solutions	11 locations (listed on the posting)	Oct 1, 2026	Oct 9, 2026	Senior
Senior Director, Integrated Solutions - E&O Leader	8 locations (listed on the posting)	Oct 1, 2026	Oct 9, 2026	Senior
Associate Director, Finance	Marlborough, MA	Oct 1, 2026	Oct 9, 2026	Senior
Regulatory Compliance Engineer II	Remote - Massachusetts	Sep 30, 2026	Oct 9, 2026	Mid
Bioprocessing Sales Specialist	4 locations, including North Carolina, Remote	Sep 24, 2026	Oct 9, 2026	Mid
Senior Manufacturing Engineer	Marlborough, MA	Sep 24, 2026	Oct 9, 2026	Senior
QA Inspector II	Rancho Dominguez, CA	Sep 23, 2026	Oct 9, 2026	Mid
Senior Manager, Quality	Marlborough, MA	Sep 23, 2026	Oct 9, 2026	Senior
Bioprocessing Sales Specialist, Engineered Systems	Remote - North Carolina	Sep 23, 2026	Oct 9, 2026	Mid
Full Stack Web Developer	Waltham, MA	Sep 23, 2026	Oct 9, 2026	Mid
Quality Control Inspector I	Hopkinton, MA	Sep 23, 2026	Oct 9, 2026	Entry
Bioprocessing Sales Specialist, Fluid Management OEM	7 locations, including Massachusetts, Remote	Sep 23, 2026	Oct 9, 2026	Mid
Senior Field Applications Scientist	Remote - China	Sep 23, 2026	Oct 9, 2026	Senior
Human Resources Business Partner	Waltham, MA	Sep 23, 2026	Oct 9, 2026	Senior
R&D Project Manager	Waterford, Ireland	Sep 23, 2026	Oct 9, 2026	Mid
Facilities Manager	Clifton Park, NY	Sep 23, 2026	Oct 9, 2026	Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 73 jobs →

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT00812058	A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression	Phase 2	Completed	2008-11	2010-12 (actual)
NCT00660335	Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas	Phase 3	Completed	2008-03	2009-10 (actual)
NCT00322764	Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression	II	Completed	2006-03	Not listed
NCT00036231	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction	Phase 3	Terminated	2002-04	Not listed
NCT00060515	RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease	Phase 1	Terminated	Not listed	Not listed
NCT00036244	Synthetic Human Secretin in Children With Autism	Phase 3	Completed	2002-04	Not listed

NIH awards 22

Annual award amounts. Total $5.5M.

Sep 17, 2002 NIH award 1R43MH065765-01 FY2002: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI BOISMENU, RICHARD; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. Improved Secretin Analogs for the Treatment source ↗
Apr 30, 1999 NIH award 5R44CA071255-03 FY1999: $312,427 awarded for that fiscal year; activity R44 (SBIR); PI RUSCHE, JAMES R; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. BFGF AND VEGF ANTAGONISTS FOR CANCER TREATMEN source ↗
Apr 8, 1999 NIH award 1R43CA081908-01 FY1999: $99,660 awarded for that fiscal year; activity R43 (SBIR); PI MAROLEWSKI, ARIANE E; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. HEPARANASE INHIBITORS FOR USE IN METASTAT source ↗
Apr 10, 1998 NIH award 2R44CA071255-02 FY1998: $437,572 awarded for that fiscal year; activity R44 (SBIR); PI RUSCHE, JAMES R; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. BFGF AND VEGF ANTAGONISTS FOR CANCER TREATMEN source ↗
Nov 14, 1996 NIH award 7R43EY011333-02 FY1996: $96,529 awarded for that fiscal year; activity R43 (SBIR); PI WITT, DANIEL P; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. DEVELOPMENT OF GROWTH FACTOR ANTAGONISTS source ↗
Mar 24, 1995 NIH award 1R43CA066432-01 FY1995: $99,998 awarded for that fiscal year; activity R43 (SBIR); PI DALY, THOMAS J; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. DEVELOPMENTOF CHEMOKINES FOR MYELOPROTECTION source ↗
May 22, 1992 NIH award 5R01AI029825-03 FY1992: $422,926 awarded for that fiscal year; activity R01 (OTHER_NIH); PI POTTS, BARBARA J.; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. NEUTRALIZATION RESISTANT VARIANTS OF H source ↗
Sep 18, 1991 NIH award 1R43CA055423-01 FY1991: $27,274 awarded for that fiscal year; activity R43 (SBIR); PI LAI, CHEE; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. GENERATION OF PF4 POLYETHYLENE GLYCOL CONJUGATES source ↗
Sep 10, 1991 NIH award 1R43AI031712-01 FY1991: $49,984 awarded for that fiscal year; activity R43 (SBIR); PI HIGGINS, PAUL; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. ANTIBODY HETEROCONJUGATES FOR TREATMENT OF SIV I source ↗
May 7, 1991 NIH award 5R01AI029825-02 FY1991: $342,830 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PUTNEY, SCOTT D; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. NEUTRALIZATION RESISTANT VARIANTS OF HIV source ↗
1991 NIH contract (government contract; not a grant and not an investment round) N01CP095645-005 FY1991: activity N01 (OTHER_NIH); PI RUSCHE, JAMES; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PRODUCTION OF PURIFIED RECOMBINANT VIRAL PROTEINS PRODUC source ↗
May 9, 1990 NIH award 1R01AI029825-01 FY1990: $329,644 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PUTNEY, SCOTT D; recipient as written: REPLIGEN CORPORATION, WALTHAM, MA. NEUTRALIZATION RESISTANT VARIANTS OF HIV source ↗
1990 NIH contract (government contract; not a grant and not an investment round) N01CP095645-001 FY1990: $364,731 awarded for that fiscal year; activity N01 (OTHER_NIH); PI RUSCHE, JAMES; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PRODUCTION OF PURIFIED source ↗
1990 NIH contract (government contract; not a grant and not an investment round) N01CP095645-003 FY1990: activity N01 (OTHER_NIH); PI RUSCHE, JAMES; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PRODUCTION OF PURIFIED RECOMBINANT VIRAL PROTEINS PRODUC source ↗
1989 NIH contract (government contract; not a grant and not an investment round) N01CP071129-008 FY1989: activity N01 (OTHER_NIH); PI PUTNEY, SCOTT; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PREPARATION OF ANTISERA RETROVIRUS POOLS ANTIGENS AND source ↗
1989 NIH contract (government contract; not a grant and not an investment round) N01CP095645-000 FY1989: $458,765 awarded for that fiscal year; activity N01 (OTHER_NIH); PI RUSCHE, JAMES; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PRODUCTION OF PURIFIED source ↗
1988 NIH contract (government contract; not a grant and not an investment round) N01CP071129-007 FY1988: $244,510 awarded for that fiscal year; activity N01 (OTHER_NIH); PI PUTNEY, SCOTT; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PREPARATION OF ANTISER source ↗
1987 NIH contract (government contract; not a grant and not an investment round) N01CP071129-005 FY1987: $200,000 awarded for that fiscal year; activity N01 (OTHER_NIH); PI PUTNEY, SCOTT; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PREPARATION OF ANTISER source ↗
1986 NIH contract (government contract; not a grant and not an investment round) N01AI062558-001 FY1986: activity N01 (OTHER_NIH); PI PUTNEY, SCOTT; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PREPARATION OF ANTISERA RETROVIRUS POOLS ANTIGENS AND source ↗
1986 NIH contract (government contract; not a grant and not an investment round) N01AI062558-000 FY1986: $942,912 awarded for that fiscal year; activity N01 (OTHER_NIH); PI PUTNEY, SCOTT; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PREPARATION OF ANTISER source ↗
1986 NIH contract (government contract; not a grant and not an investment round) N01CP071129-001 FY1986: activity N01 (OTHER_NIH); PI PUTNEY, SCOTT; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PREPARATION OF ANTISERA RETROVIRUS POOLS ANTIGENS AND source ↗
1986 NIH contract (government contract; not a grant and not an investment round) N01CP071129-000 FY1986: $942,912 awarded for that fiscal year; activity N01 (OTHER_NIH); PI PUTNEY, SCOTT; recipient as written: REPLIGEN CORPORATION, WALTHAM, . PREPARATION OF ANTISER source ↗